What defines the quality of patient care in tinea pedis?

Objectives  The aim of this study has been to evaluate patients with tinea pedis for their demographic data and attitudes affecting the treatment of disease, and to compare the in vitro activity of 10 antifungal agents and to relate them to their in vivo activity.

[1]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[2]  F. Crawford.  Athlete's foot. , 2009, Clinical evidence.

[3]  A. Koç,et al.  In vitro susceptibility testing of dermatophytes: comparison of disk diffusion and reference broth dilution methods. , 2004, Diagnostic microbiology and infectious disease.

[4]  G. Krishnaswamy,et al.  Dermatology for the practicing allergist: Tinea pedis and its complications , 2004, Clinical and molecular allergy : CMA.

[5]  D. Hospenthal,et al.  The role of antifungal susceptibility testing in the therapy of candidiasis. , 2004, Diagnostic microbiology and infectious disease.

[6]  Aditya K. Gupta,et al.  In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity , 2003, The British journal of dermatology.

[7]  M. Ghannoum,et al.  Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. , 2003, Infectious disease clinics of North America.

[8]  B. L. Hainer.  Dermatophyte infections. , 2003, American family physician.

[9]  B. Berman,et al.  Topical treatment of common superficial tinea infections. , 2002, American family physician.

[10]  J. Guarro,et al.  In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains , 2001, Antimicrobial Agents and Chemotherapy.

[11]  M. Rinaldi,et al.  Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method , 2001, Journal of Clinical Microbiology.

[12]  S. Rand.  Overview: The treatment of dermatophytosis. , 2000, Journal of the American Academy of Dermatology.

[13]  M. Rinaldi,et al.  Dermatophytosis: Epidemiological and microbiological update , 2000 .

[14]  B. Elewski,et al.  A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. , 2000, Journal of the American Academy of Dermatology.

[15]  M. Ghannoum,et al.  Antifungal Susceptibility Testing of Dermatophytes: Establishing a Medium for Inducing Conidial Growth and Evaluation of Susceptibility of Clinical Isolates , 2000, Journal of Clinical Microbiology.

[16]  J. Marley,et al.  Topical treatment of interdigital tinea pedis: Terbinafine compared with clotrimazole , 1999, The Australasian journal of dermatology.

[17]  D. Roseeuw,et al.  Achilles foot screening project: preliminary results of patients screened by dermatologists , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  E. Haneke.  Achilles foot‐screening project: background, objectives and design , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  D. Torgerson,et al.  Systematic review of topical treatments for fungal infections of the skin and nails of the feet , 1999, BMJ.

[20]  M. Burattini,et al.  Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. , 1998, Diagnostic microbiology and infectious disease.

[21]  G. Levy,et al.  Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. , 1998, International journal of dermatology.

[22]  T. Kimura,et al.  Tinea pedis outbreak in swimming pools in Japan. , 1997, Public health.

[23]  J. Rex,et al.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi , 1997, Journal of clinical microbiology.

[24]  J. van Houwelingen,et al.  [Terbinafine versus miconazole in patients with tinea pedis]. , 1996, Nederlands tijdschrift voor geneeskunde.

[25]  M. Ollert,et al.  Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group , 1995, Antimicrobial agents and chemotherapy.

[26]  R. Hay,et al.  A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 1OO mg/day in plantar‐type tinea pedis , 1995, The British journal of dermatology.

[27]  C. Goh,et al.  IN VITRO EVALUATION OF GRISEOFULVIN, KETOCONAZOLE, AND ITRACONAZOLE AGAINST VARIOUS DERMATOPHYTES IN SINGAPORE , 1994, International journal of dermatology.

[28]  D. Massart,et al.  Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study , 1994, The British journal of dermatology.

[29]  J. Williams.  Deep Vein Thrombosis in a Skier's Leg. , 1994, Physician and sportsmedicine.

[30]  H. C. Williams,et al.  The epidemiology of onychomycosis in Britain , 1993, The British journal of dermatology.

[31]  C. Dolan.  Bailey and Scott's Diagnostic Microbiology , 1991 .

[32]  P. Rees,et al.  Opportunistic mycoses. , 1981, The American Journal of Nursing.

[33]  H. Jones,et al.  Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. , 1981, Archives of dermatology.

[34]  Yvonne M Clayton,et al.  Book Review: Medically Important Fungi: A Guide to Identification , 1977 .

[35]  D. Larone.  Medically Important Fungi: A Guide to Identification , 1976 .

[36]  C. Lacaz.  A textbook of medical mycology. , 1967 .